Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03159936 · ClinicalTrials.gov registry record · Early Phase 1
Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)
A Early Phase 1 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03159936 is a Early Phase 1 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT03159936, a Early Phase 1 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE.
Interventions
- BIOLOGICAL Tofacitinib citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2020-06-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03159936
The ClinicalTrials.gov registry entry for NCT03159936 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tofacitinib citrate is the first listed.
NCT03159936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03159936 about?
NCT03159936 is a clinical study titled "Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)". Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE.
What is the current status of trial NCT03159936?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2017-04-03. Estimated completion is 2020-06-10.
What interventions are being tested in trial NCT03159936?
The interventions under investigation include: Tofacitinib citrate (BIOLOGICAL).
Who is sponsoring clinical trial NCT03159936?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.